Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

2cureX Temettü

Temettü kriter kontrolleri 0/6

2cureX şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Ödeme oranı

Sektör ortalama getirisi	1.6%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Hisse başına kazanç	-SEK 1.50
Temettü verim tahmini	n/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: 2CUREX şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: 2CUREX şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

2cureX Piyasaya Karşı Temettü Getirisi

2CUREX temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (2CUREX)	n/a
Pazarın Alt %25'i (SE)	1.5%
Pazarın En İyi %25'i (SE)	4.4%
Sektör Ortalaması (Medical Equipment)	1.6%
Analist tahmini (2CUREX) (3 yıla kadar)	n/a

Önemli Temettü: 2CUREX şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, 2CUREX şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: 2CUREX şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: 2CUREX herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

2cureX Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

2cureX AB (publ) Approves the Election of New Board Members

First half 2024 earnings released: kr0.54 loss per share (vs kr0.89 loss in 1H 2023)

2cureX AB (publ) to Report Fiscal Year 2024 Final Results on Apr 24, 2025

2cureX AB (publ) Announces CEO Changes

2cureX AB (publ) to Report Q4, 2024 Results on Feb 20, 2025

No independent directors

2curex AB (publ) Elects Grith Hagel as a New Board Member

Full year 2023 earnings released: kr1.75 loss per share (vs kr1.69 loss in FY 2022)

2cureX AB (publ), Annual General Meeting, May 23, 2024

2cureX AB (publ) to Report Q2, 2024 Results on Aug 22, 2024

2cureX AB (publ) Receives Ethical Approval for HIPEC Clinical Trial

Third quarter 2023 earnings released: kr0.58 loss per share (vs kr0.47 loss in 3Q 2022)

2Curex AB (Publ) Appoints Tonni Bülow-Nielsen as Board Member and Chairman

New minor risk - Share price stability

2curex Launches Its First Two IndiTreat® Products Ce-Marked Under the New Ivd Regulation

New major risk - Financial position

First quarter 2023 earnings released: kr0.43 loss per share (vs kr0.45 loss in 1Q 2022)

Chief Executive Officer recently bought kr136k worth of stock

Chief Executive Officer recently bought kr136k worth of stock

Full year 2022 earnings released: kr1.69 loss per share (vs kr1.15 loss in FY 2021)

Full year 2022 earnings released: kr1.69 loss per share (vs kr1.15 loss in FY 2021)

2cureX AB (publ) Appoints Michel Klimkeit to Board of Director

2cureX AB (publ) to Report Q4, 2023 Results on Feb 22, 2024

Third quarter 2022 earnings released: kr0.47 loss per share (vs kr0.31 loss in 3Q 2021)

High number of new and inexperienced directors

2cureX AB (publ), Annual General Meeting, May 25, 2023

2cureX Announces Board Change

Chief Executive Officer recently bought kr84k worth of stock

We're Not Very Worried About 2cureX's (STO:2CUREX) Cash Burn Rate

2cureX AB (publ) Presents Inditreat® Clinical Results At the Society for Functional Precision Medicine

High number of new and inexperienced directors

Manuel Fernández Joins 2cureX as Director of Quality Assurance and Regulatory Affairs

2cureX AB (publ) Announces Management Changes

2cureX (STO:2CUREX) Is In A Good Position To Deliver On Growth Plans

2cureX Launches IndiTreat mCRC Start Test to Guide First Line Treatment

We're Not Very Worried About 2cureX's (STO:2CUREX) Cash Burn Rate

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

2cureX Announces New Development of the IndiTreat Technology Allows Prediction of Response to Anti-Angiogenic Drugs in Colorectal Cancer

High number of new and inexperienced directors

We're Interested To See How 2cureX (STO:2CUREX) Uses Its Cash Hoard To Grow

2Curex AB (Publ) Clinical Partner, University Hospital Vejle, Presents Positive Results of Thnditreat®-Guided Clinicaical Trial in Third Line Metastatic Colorectal Cancer At the Asco 2021 Annual Meeting

Co-Founder exercised options to buy kr7.6m worth of stock.

2cureX AB (publ) Announces Clinical Trial of Inditreat®-Guided Treatment of Metastatic Colorectal Cancer

2cureX AB (publ) to Report Fiscal Year 2021 Results on Feb 24, 2022

Shareholders Of 2cureX (STO:2CUREX) Must Be Happy With Their 280% Total Return

2cureX AB's IndiTreat® Selected to Prestigious Multinational Ovarian Cancer Project

New 90-day high: kr22.60

Chief Financial Officer has left the company

2cureX Appoints Kenneth Graabek Johansen as New CFO, Effective 1 February 2021

2cureX Announces Last Patient Treated in the World's First Interventional Trial with 3D Microtumors as Guide for Choice of Cancer Treatment

New 90-day high: kr17.65

2cureX Announces Management Changes

2cureX AB (publ), Annual General Meeting, May 27, 2021

How Does 2cureX's (STO:2CUREX) CEO Salary Compare to Peers?

New 90-day low: kr16.25

2cureX Announces Last Patient Successfully Enrolled in the Worlds First Interventional Trial with 3D Microtumors as Guide for Choice of Cancer Treatment

New 90-day low: kr17.30

2cureX launches world's first CE-marked microtumor test service

New 90-day high - kr22.50

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin